Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.

A rout in Hims & Hers Health Inc. has delivered a windfall to short sellers, as investors bet against the telehealth company’s business.

Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the US patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims’ new strategy to launch a copycat pill but also goes after shots that mimic Wegovy and its sister drug Ozempic. The move marks a more aggressive approach for Novo under Chief Executive Officer Mike Doustdar. Until now, the drugmaker’s legal strategy focused on the way that companies like Hims market their products. Novo said this is the first time it has sued over patent infringement for compounded semaglutide. (Source: Bloomberg)

Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs. Bloomberg's Sam Fazeli reports. (Source: Bloomberg)

Novo’s shares plunged on Thursday after telehealth firm Hims & Hers Health Inc. launched a cheaper copycat version of its Wegovy pill that the Danish drugmaker says is illegal. Michael Shah of Bloomberg Intelligence has more. (Source: Bloomberg)